Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Gastrointestinal 1Breast 1

Conditions

Mesothelioma 1Lung Neoplasms 1Gastrointestinal Neoplasms 1Esophageal Neoplasms 1Breast Neoplasms 1

Interventions

Surveys and Questionnaires 7Nivolumab 5atezolizumab 3Radiosurgery 3Blood Specimen Collection 3pertuzumab 2pembrolizumab 2pazopanib 2cemiplimab 2amminedichloro(2-methylpyridine)platinum(II) 2alectinib 2Magnetic Resonance Spectroscopy 2Interviews as Topic 2Drug Therapy 2Capecitabine 2tepotinib 1talazoparib 1selpercatinib 1pralsetinib 1ponatinib 1pemigatinib 1palbociclib 1motexafin gadolinium 1montanide ISA 51 1mannide monooleate 1itacitinib 1ipatasertib 1fludarabine 1entrectinib 1durvalumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Gastrointestinal Neoplasms × Plicamycin × Breast × Clear all
NCT01624090 2019-12-30

Mithramycin for Lung, Esophagus, and Other Chest Cancers

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
16 enrolled 13 charts
BreastGastrointestinalOther solid neoplasmThoracic

Breast Neoplasms, Esophageal Neoplasms, Gastrointestinal Neoplasms, Lung Neoplasms, Mesothelioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡